Helicobacter pylori is one of the most common infections found in humans. It was first identified in 1982 and by 1989 had been associated with gastric inflammation and ulcers in adults and children. During the 1990's evidence emerged of its etiologic role in stomach cancers in adults. That the infection is common and may have serious consequences, has led to an avalanche of research during the last twenty years. During this time, there have been many studies on children which have sought an effective and safe treatment to eradicate the infection, but as yet, no therapy regimen has been found which is always effective and safe. This article provides information, from a pediatric point of view, on the major developments in the therapeutics and therapy of H. pylori infection. It examines first-line treatment regimens, evaluates the efficacy of the main drugs used in the management of (primary) H. pylori infection in children, assesses the potential for the use of probiotics and sequential therapy, examines therapeutic options after failure of initial treatment, and discusses factors affecting eradication rate, including antibiotic resistance, adherence to therapy, and bacterial factors.
Helicobacter pylori is the source of a highly prevalent, serious, and chronic infection that has been associated causally with a diverse spectrum of gastrointestinal disorders including peptic ulcer disease, gastric adenocarcinoma, and gastric mucosaassociated lymphoid tissue lymphoma (1) . In both developed and developing countries, H. pylori is most frequently acquired during childhood, and is associated with family size, clustering in families, low socioeconomic status and education. In general, it is hypothesized that spontaneous eradication ofH. pylori infection is extremely rare.
In recent years, the success of eradication therapies has declined, in part due to the development of H. pylori resistant strains. Current guidelines for children still recommend as first-line options triple therapies consisting ofa proton pump inhibitor (PPI), plus two antibiotics (choosing two of the following: amoxicillin, clarithromycin, or metronidazole) for I to 2 weeks (2), though new strategies may be required for treatment both in adults and children.
In order to give convenient access to a multifaced fund of current information on the major developments in the therapy of H. pylori infection in children, our aims are to: (a) review the therapeutic efficacy of first-line triple treatment regimens in children on the basis of evidence from case studies, and comparative (randomized and non-randomized) studies; (b) review the latest in emerging therapeutics (probiotics, sequential therapy) for the management of H. pylori infection in children; (c) comprehensively review factors which may affect H. pylori eradication and play a role in predicting the therapeutic outcome in children, including antibiotic resistance, adherence to medication, and bacterial factors; (d) discuss the latest in re-treatment of children who fail to eradicate H. pylori with their first-line therapies.
First-line H. pylori eradication therapies Methods
Using MEDLINE, studies which evaluated the efficacy of triple therapies for H. pylori eradication in children with gastroduodenal disease were identified between 1994 and 2009. The study sources included a Medline search using the key words "Helicobacter pylori" or "Campylobacter pylori", "treatment", "therapy", and "children". Inclusion criteria for eligible studies included children with a referral diagnosis ofupper abdominal complaints but no history of previous treatment with H. pylori eradication, upper gastrointestinal endoscopy to assess H. pylori status at initial visit, and full papers only for which details are available in English regarding the medication used, study design, location of study subjects, endoscopic and/or histologic findings at baseline, and the proportion of evaluable subjects in whom H. pylori was eradicated after treatment. Studies were excluded which did not carry out follow-up endoscopies with gastric biopsies or did not use urea breath tests (UBT) to detect the post-treatment H. pylori status. Duplicate studies were also excluded.
RESULTS
Among case series of triple therapies for H. pylori eradication in children with gastroduodenal disease, we identified 16 published studies over the last two decades (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , with between 12 and 98 treated patients with between 51% and 92% having the infection eradicated, but no two of the triple therapies was the same. The most commonly tested regimen contained a combination of PPI, clarithromycin, and amoxicillin, followed by triple therapies containing PPI, clarithromycin, and nitroimidazoles, or bismuth, clarithromycin, and nitroimidazoles (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . The reasons for the great variability of the eradication rates observed in the studies include small sizes of study populations, differences between study populations, and variation in the total daily dose, dosing frequency and duration of treatment components, as well as in time of posttreatment follow-up and methods used to assess eradication after treatment. We have summarized these results by calculating the overall percentage of patients with successful eradication, which was 78% (95% CI, 72-84).
We also identified 11 comparative studies (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) of eradication triple therapies for H. pylori in children with gastroduodenal disease [2 nonrandomized (21) (22) , 5 randomized (23-27), and 4 randomized, double blind (19) (20) (28) (29) ] published between 1994 and 2008, comparing two or more treatment regimens (Table I ). The eradication rates in the 5 randomized studies varied between 84% and 92% according to intention-to-treat analysis, and between 50% and 89% per protocol. In contrast, in the four randomized, double-blind, placebocontrolled studies the range of eradication rates after triple therapy with PPI, clarithromycin and amoxicillin, or PPI, tinidazole and amoxicillin was narrower, varying between 68% and 74% according to intention-to-treat analysis, and between 69% and 80% per protocol.
Emerging therapeutics
Sequential therapy. Sequential therapy for H. pylori implies adding more antibiotics to the treatment regimen but giving them in sequence rather than giving all drugs together. Typically, the sequential treatment is represented by a 5-day dual therapy (PPI plus amoxicillin) followed by a 5-day triple therapy (PPI, clarithromycin, and tinidazole) (30) (31) (32) . The dual scheme includes amoxicillin, which is able to eradicate H pylori in some patients and to reduce the bacterial load in all the remaining cases, without inducing bacterial resistance. Indeed, it has been found that regimens containing amoxicillin may prevent the Selection of secondary clarithromycin resistance. At this stage, the second part of treatment (clarithromycin and tinidazole) acts to eradicate a rather small residual population of viable organisms. The weakness of clarithromycin is that random mutation in the H. pylori 23S ribosome gene can prevent binding of the antibiotic so that it is no longer effective. Likewise, nitroimidazoles become ineffective when a random mutation inactivates the rdxA gene so that the antibiotic is no longer metabolized to its bacteria-toxic form. However, reduction of the H. pylori population before it is exposed to clarithromycin or tinidazole minimizes the probability of a mutation.
Sequential therapy is promoted as a novel, highly effective first-line anti-H. pylori therapy and thus as an alternative for PPI-triple therapy. In a recent prospective, double-blind, controlled study performed by Vaira et al. in two Italian hospitals (30) , 300 adults with dyspepsia or peptic ulcers were randomly assigned to a 10-day sequential regimen (pantoprazole, amoxicillin, and placebo taken for 5 days followed by pantoprazole, clarithromycin, and tinidazole taken for 5 days) or standard 10day therapy (pantoprazole, clarithromycin, and amoxicillin). Vaira et al. showed a 89% eradication rate for the sequential regimen versus 77% for the standard treatment (30) . More important, the infection was significantly eradicated in patients with isolated clarithromycin resistance who received sequential therapy compared with patients who received standard therapy (88.9% vs 28.6% ; p = 0.0034). Two recent meta-analyses of clinical trials of sequential therapy confirm that 10-day sequential therapy is superior to 7-or 10-day standard triple therapy for H. pylori treatment-naive patients (31) (32) .
Only one trial has been performed in children (Table I ). In a prospective study performed by Francavilla et al. in one Italian hospital (33) , 78 consecutive children with H. pylori infection and dyspeptic symptoms were randomized to receive either 10-day sequential treatment or standard 7-day triple therapy. Francavilla et al. showed a 97.3% eradication rate for the sequential regimen versus 75.7% for the standard treatment (33) . In this study, however, data on anti-microbial resistance are missing.
On the basis of the above, sequential therapy is very promising. However, most studies with the sequential regimen come from Italy, which may limit generalizability (31) . Before this regimen can be accepted by other countries, independent confirmation in treatment-naive adults as well as children from other groups outside Italy is urgently needed. For example, sequential therapy has not been compared with standard triple therapy given for 14 days (31) . In the United States, 14-day regimens of standard triple therapy are approved by the Food and Drug Administration (FDA) and widely used. Because antimicrobial resistance is largely responsible for the poor eradication rates with standard triple therapy, and patterns of antimicrobial resistance vary geographically, it will be also important to study sequential therapy in randomized controlled trials around the world, in countries with high as well as low anti-microbial resistance (31) . One potential disadvantage to sequential therapy is that patients with failed eradication would have limited options for further treatment because they would already have received 3 different antibiotics. Indeed, the Authors of clinical trials of sequential therapy did not provide information on how they handled their failures. We therefore do not know how the failures of sequential therapies should be retreated, nor do we know whether sequential therapy may replace PPI -based quadruple therapy as a rescue therapy in adults as well as in children.
Supplementation with probiotics.
Beneficial effects of probiotics in gastrointestinal diseases are generally explained by two possible mechanisms: (i) the biological modulation of the microbiota; and (ii) the modulation of the immune system in the gastrointestinal tract (34) . At present, the most studied probiotics are the lactic acid-producing bacteria, particularly Lactobacillus species. Most probiotic strains, especially lactobacilli, have exhibited antagonistic properties against H. pylori in vitro.
Several studies using murine models have shown that probiotic treatment, although it is unable to clear H. pylori, is effective in reducing bacterial colonization and decreasing gastric inflammation in H. pylori-infected mice. It has been postulated, on the basis of the results of in vitro and animal studies, that probiotics could possibly compete with and down-regulate H. pylori infection in humans (34) . Though utilization of probiotics alone does not lead to the eradication of H. pylori, a growing body of recent evidence suggests that regular intake 
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Histologic gastritis (20) l-wk of amoxicillin,c1arithromycin andomeprazole 10 (35) . The results show that the suppressive effect on H. pylori colonization in children requires the presence of live bacteria, and that this effect depends on the probiotic strain used. A few studies have directly assessed the effect of the administration of probiotics on H. pylori gastritis by the histologic examination ofgastric biopsies (34) . These studies have shown that the administration of probiotics improves H. pylori gastritis and diminishes H. pylori density. The effect was statistically significant but weak (34) . It has been also postulated that the co-admnistration of probiotics with the PPIantibiotic regimen would have a positive impact on H. pylori therapy-related side effects. However, this remains unproven because no study has evaluated the composition of intestinal microflora.
At present, in the pediatric population, five randomized studies have evaluated whether consumption of probiotics could increase H. pylori eradication rates and reduce the side effects of treatment (36) (37) (38) (39) (40) .These trials do not provide evidence on the beneficial effect in children of supplementation of probiotics to triple therapy for eradicating H. pylori infection nor for positively (16, 19, (43) (44) (45) (46) S: sensitive; R: Resistant affecting therapy-related symptoms and overall treatment tolerance. However, the five studies are all based on relatively small samples and lack the statistical power necessary to detect an important effect of the probiotics. Finally, in most studies, the effect of probiotic treatment on H. pylori infection in children has been estimated indirectly by VBT. We conclude that multicenter, placebo-controlled studies on larger series ofchildren are needed to demonstrate any benefit of probiotics in the management of H. pylori infection in children, including its effect on the severity ofH. pylori gastritis. Long-term studies are also needed on children to prove whether the persistent suppressive effect of probiotics on H. pylori and its associated gastritis could prevent diseases such as gastric cancer or peptic ulcer.
Factors affecting eradication rate
Several factors, such as antibiotic resistance, compliance to therapy, and bacterial factors have been found to affect the efficacy of standard triple therapies.
Antibiotic resistance. In recent years in Europe, the resistance rate of H. pylori strains to first-line drugs used to eradicate H. pylori in children was investigated through a standardized questionnaire, the details of which included history of any previous specific anti-H. pylori treatment, and antibiotic susceptibility testing to clartithromycin, metronidazole, and amoxicillin (41) . In that investigation, Koletzko et al. showed that primary resistance to clarithromycin, metronidazole and amoxicillin was present in 20%, 23%, and 0.6% of H. pylori strains, respectively, while secondary resistance in 42%, 35%, and 0.6% of the strains recovered after at least one failed treatment for H. pylori (41) . The use of clartithromycin for other indications, mainly for respiratory tract infections, seemed to be the major risk factor for development of primary resistance. Children who grew up in Southern Europe had a 2.25 times higher risk for primary clarithromycin resistance than children who grew up in Northern, Eastern or Western Europe (41) . On the other hand, Koletzko et al. also showed that children born in Asia, Africa or the Middle East had a 2.4 times higher risk for primary metronidazole resistance than patients of equal age and sex born in Europe (41) . Iterative metronidazole treatments for parasitic or diarrheal diseases in children originating from Africa and Asia may be incriminated in the increased primary resistance rates of metronidazole recorded by Koletzko et al. in these pediatric populations.
It appears that the effect ofresistance on treatment outcome is less pronounced for metronidazole than for clarithromycin. The analysis by Megraud (42) of 20 reports providing results in relation to H. pylori susceptibility to metronidazole and clarithromycin during the period 1999-2003 showed that clarithromycin resistance reduced efficacy by 69.5%(95% CI, 62.4 to 76.6%) from 87.8% (95% CI, 83.1 to 92.5%) to 18.3% (95% CI, 13.0 to 23.6%), compared with metronidazole resistance, which reduced efficacy by 24.4 % (95% CI, 13.5 to 35.3%) from 97.0% (95% CI, 95.2 to 98.8%) to 72.6% (95% CI, 61.8 to 83.3%). Nonetheless, when the metronidazole resistance rate reaches 40%, as is the case, for instance, for children living or born in the Middle or Far East where the use of metronidazole is widespread even in children, this antibiotic should not be used.
What do these data imply for children? There is very limited information on the impact of clarithromycin and metronidazole resistance on H. pylori eradication in children. We have identified few clinical trials over the last two decades which evaluate the clinical outcome of H. pylori triple therapies with respect to pre-treatment susceptibility testing to clarithromycin and metronidazole (16, 19, (43) (44) (45) (46) . Despite the very limited number and power of pediatric clinical trials including susceptibility testing, the effect of resistance on treatment outcome was more pronounced for clarithromycin than for metronidazole (Table II ). In the case of clarithromycin resistance alone, when the triple therapy with PPI, amoxicillin, and clarithromycin is used, there is a 63% decrease in eradication rates. Yet, in clarithromycin-resistant strains the combination of PPI, amoxicillin, and metronidazole was much more successful than the combination of PPI, amoxicillin, and clarithromycin. In cases of metronidazole resistance alone, when triple therapies consisting of either PPI, amoxicillin, metronidazole, or bismuth compounds, amoxicillin, and metronidazole were used, there were 47 and 38% decreases in eradication rates, respectively (Table II) .
It is quite clear that clarithromycin resistance is associated with a high rate of treatment failure when clarithromycin-containing regimens are employed. Thus, clarithromycin should be avoided without prior antimicrobialsensitivityiflocal primary clarithromycin resistance exceeds 15-20%; moreover 'pre-treatment clarithromycintesting is practical and cost effective.
Adherence to medication. Duration, schedule, formulation, palatability, cost, and adverse effects of medication all are factors that contribute to adherence to medication. The challenge of adherence to a medication regimen in pediatric patients needs not only the child's cooperation but also the involvement of the patient's family including a devoted, persistent, and adherent parent or caregiver. Collecting adherence data from subjects is now considered an essential part of clinical trials. However, adherence to medication regimens was not monitored in several pediatric studies (3-4, 6, 8-14, 16, 18,22,24,27-28Ĩ n pediatric case series, the rates of adherence to triple therapies were of 87% (17) to 100% (7, 15) . Randomized pediatric trials (19, 26, 29, 33) reported adherence rates of 88 to 98 percent among children mostly receiving l-wk regimen of medication or placebo, with the exception of one clinical trial (20) reporting an adherence rate of 71% to the above regimen. Data on drug adherence was often reported as dichotomy (adherence vs nonadherence). Nonetheless, some studies considered rates of greater than 75% to be acceptable (17, 19) , whereas others considered rates of greater than 90% (26) or 95% (33) to be mandatory for adequate adherence. Adherence to medication regimen or placebo was monitored in all pediatric studies by indirect methods of measurement of adherence including pill counts or ascertaining the amount of suspension left in the bottle at the control visit (5, 17, 19, 21, 29) . Although the simplicity of this method has been attractive to some investigators, this method is subject to many problems, because patients may discard pills or suspension before visits in order to appear to be following the regimen. In addition, this method provides no information on dose timing, which may be important in determining clinical outcomes. In other pediatric studies indirect methods of measurement of adherence included questioning the patient (or using a questionnaire) (4, 7, 15) , but questioning the patient can be susceptible to misrepresentation and tends to result in the physician's overestimating the patient's adherence. This underscores the thought that the body of knowledge on children's adherence to medication regimens (or placebo) for H. pylori eradication is inadequate in many respects and has not quantified the true effect of nonadherence on the failure rates of various medication regimens.
Bacterial factors. Among bacterial factors, specific virulence-associated H. pylori genotypes and the density of colonization seem to influence the level of gastric inflammation and epithelial damage.
cagA status. CagA is a high molecular weight immunogenic protein encoded by the cagA gene, located at one end of the cag pathogenicity island (PAl). H. pylori is divided into cagA-positive and cagA-negative strains, and there is increasing evidence that infection with strains containing a cagA gene are associated with a greater inflammatory response and an increased risk ofadverse outcomes than infections with strains lacking the cagA gene. Many pediatric studies have been published that have examined the association between cagA-positive status detected by genetic tests and gastric mucosal pathology. From a biologic point of view, the relationship between the outcome of H. pylori eradication therapy and cagA status has been explained by the severity of gastric mucosal inflammation (47) . The presence of the cag PAl, as detected by cagA, induces the secretion of interleukin 8, a proinflammatory cytokine, by the epithelial cells, and an increased inflammation of the gastric mucosa in comparison to those harboring cagA-Iacking strains. Patients with severe histologic changes in the antral mucosa have been associated with significantly higher cure rates compared with those with milder inflammation (48). In fact, the cure rates in patients infected with cagA-positive strains have been reported to be significantly higher than in those with cagA-negative strains (47) . As gastric inflammation increases mucosal blood flow, it has been hypothesized this may help the diffusion of antibiotics. Nonetheless, despite the limited experience in children, Lopez-Brea et al. showed in 57 pediatric patients that the cagA status was not an important factor in treatment failure in the eradication of H. pylori following the triple therapy containing metronidazole, amoxicillin and bismuth citrate (46) . vacA gene status. Unlike cagA, the vacA gene is present in all strains ofH. pylori. Two types of signal region (s1 and s2) and middle region (m1 and m2) exist. The vacA s2 type blocks the vacuolating activity, while infection with strains of the vacA s1 genotype has been linked to severe gastric inflammation with enhanced cytoxin activity (47) . In general, vacA s1 and m1 genotypes produce a large amount of toxin, which causes higher vacuolating activity in gastric epithelial cells, whereas vacA s2 and 1112 genotypes produce little or no toxin. Several Authors have reported a significant increased risk of eradication failure in H. pylori with vacA s2 genotype compared with s1 genotype (47) . Nevertheless, despite the very limited experience in children, Lopez-Brea et al. found no difference in eradication rates among pediatric patients infected with strains that harbored the vacA s1 or vacA s2 alleles (46) .
Intragastric H. pylori density. High H. pylori density may adversely influence the efficacy of H. pylori eradication therapy. In a study involving 28 children in whom pre-and post-treatment histologic findings were available, Shashidar et al. showed that with higher pre-treatment bacterial load, eradication of infection after PPI-based triple therapy was more difficult (12) . Thus increasing the duration of therapy may be a way to overcome the unfavourable effects caused by high H. pylori density at the start of eradication treatment. However, there is good evidence that medication adherence decreases over the treatment period, especially in children.
Re-treatment
Children who fail with their first-line treatment to eradicate H. pylori probably include a higher percentage of non-compliant subjects, others have resistant organisms. Other important factors in non-response to initial treatment include the type of antimicrobial agent, the total daily dose, the dosing interval, and the duration of the regimen.
Pre-treatment antibiotic resistance is a very important factor in non-response to initial treatment. However, the use ofa culture as a "routine practice" in children who have failedfirst-lineeradication therapies seems not to be feasible, even in research studies. Especially in children, non-invasive procedures such as UBT seem to be more feasible than followup antimicrobial testing by endoscopy. Thus, the choice of a second-line treatment is often empirical, depending on which treatment was used initially, as it would appear that re-treatment with the same regimen cannot be recommended. If a clarithromycin-based regimen were used, a clarithromycin-free regimen would most likely be used afterwards, and viceversa. Another alternative, the use of a quadruple regimen, has been proposed in children as a therapeutic option after failure of initial treatment. The very limited experience in children with a quadruple regimen containing tetracyclines has yielded discrepant results. in terms of eradication rates (15, 27) . Furthermore, there is reluctance on the part of pediatricians to prescribe the tetracycline group of antibiotics. The use of tetracyclines is contraindicated in children less than 8 years old unless the potential benefit of their administration outweighs their potential adverse effects. The very limited experience in children with a quadruple therapy containing furazolidone has yielded relatively good results (49) . However, the inclusion of furazolidone in a treatment regimen for H. pylori infection is, at least, controversial, and it does not appear to be safe (50) . Different studies have raised several concerns about this agent and its potential for possible genotoxic and carcinogenetic effects (50) . The FDA withdrew its approval for furazolidone in March 2005.
In adults, other therapies for persistent H. pylori infections have also been considered. These include a quadruple therapy containing rifabutin and ciprofloxacin, and a levofloxacin-based triple therapy. Data on the safety of rifabutin in children are limited. With respect to fluoroquinolones, most experts continue to advise against their expanded pediatric use. Finally, a bismuth-based quadruple therapy has been considered in adults as a rescue or salvage therapy. In a recent randomized trial evaluating in children the efficacy ofa bismuth-based quadruple therapy versus standard triple therapy for re-treatment of H. pylori infection, the quadruple therapy had a higher efficacy in eradicating H. pylori infection compared with the standard regimen (51) . However, more side effects were seen with the quadruple therapy (51) . Furthermore, the potential limitations of using bismuth compounds in children should also be considered. Preparing the child for whom rescue treatment is clinically necessary, for the possible side effects of available salvage therapies is very important as poor compliance and antibiotic resistance are the main reasons for therapeutic failure. plus amoxicillin and clarithromycin or amoxicillinclavulanic acid and metronidazole for Helicobacter pylori eradication in children. Dig Dis Sci 2009; 54: 1720-4.
